2019 American Transplant Congress
Randomized Controlled Trial Of Spironolactone Effect In Kidney Transplant Recipients Of Living Donors
*Purpose: Mineralocorticoid receptor antagonism prevents acute kidney injury induced by ischemia/reperfusion in rodent and pig preclinical models. In a pilot study, we showed that spironolactone…2019 American Transplant Congress
Pre-Transplant Donor-Specific IFN-γ ELISPOT as a Predictor of Allograft Rejection: A Diagnostic Test Accuracy Meta-Analysis
*Purpose: Pre-transplant interferon-γ (IFN-γ) enzyme-linked immunospot (IFN- γ ELISPOT) has been proposed as a tool to quantify alloreactivity of memory T cells and estimate the…2019 American Transplant Congress
Donor-Derived Cell-Free DNA is Associated Specifically with Antibody Mediated Injury in Patients with Renal Allograft Dysfunction
1Fundeni Clinical Institute, Bucharest, Romania, 2University of Washington, Seattle, WA
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) has been proposed as a noninvasive biomarker to differentiate rejection from other types of injury in renal allografts.*Methods: We analyzed…2019 American Transplant Congress
Management of Inactive Candidates on the Kidney Transplant Waitlist: Results from a National Survey
Department of Surgery, Johns Hopkins School of Medicine, Baltimore, MD
*Purpose: As the inactive deceased donor kidney transplant (DDKT) waitlist pool continues to grow, management of these patients has become an increasingly complex administrative undertaking.…2019 American Transplant Congress
Dosing and Exposure over 2 Years with LCP-Tacrolimus (LCPT) vs. Immediate-Release Tacrolimus (IR-Tac) in De Novo Kidney Transplantation
*Purpose: A prospective study demonstrated safe and efficacious use of LCPT in de novo kidney transplantation. This study aims to evaluate tacrolimus trough levels and…2019 American Transplant Congress
Assessment of Proteinuria Reported as Adverse Events in De Novo Renal Transplant Recipients Receiving an Everolimus-Based Regimen: 24-Month Results from TRANSFORM
1TRANSFORM Study Group, Basel, Switzerland, 2Novartis Pharma AG, Basel, Switzerland
*Purpose: mTOR inhibitors (eg, everolimus [EVR]), are thought to increase the risk of post-transplant (Tx) proteinuria (PU). Here, we assess PU onset and outcomes in…2019 American Transplant Congress
Long-Term Outcomes of Early Conversion to Sirolimus-Based Immunosuppression in Children with Living Donor Kidney Transplants
*Purpose: Following kidney transplantation (KTx), calcineurin inhibitor (CNI)-based maintenance immunosuppression (IS) can be associated with nephrotoxicity and other complications including viral infections and malignancy. Mammalian…2019 American Transplant Congress
The Molecular Profile of Kidney Allografts Unveil Specific Biomarkers for Subclinical Acute Rejection (SAR). Towards an Early Detection and a Targeted Treatment
Schena Foundation, Valenzano-Bari, Italy
*Purpose: SAR diagnosed by protocol biopsy is an independent risk factor for chronic allograft injury. We organized a molecular study on 24 AB0 compatible cadaveric…2019 American Transplant Congress
Multi-Center Validation of TruGraf V2 – A Peripheral Blood Diagnostic for Subclincal Kidney Rejection
*Purpose: Unsuspected subclinical acute rejection (subAR) is currently only detectable in 15-25% of invasive surveillance biopsies (SB) and can lead to chronic rejection and poor…2019 American Transplant Congress
Differential Effects Of Prolonged Cold Ischemia On Outcomes In Donation After Cardio Circulatory Death Versus Acute Kidney Injury Donor Kidney Transplants
Wake Forest Baptist Medical Center, Winston-Salem, NC
*Purpose: Donation after cardio-circulatory death (DCD) and acute kidney injury (AKI) deceased donor (DD) kidneys increase the organ pool but their rates of discard and…
- « Previous Page
- 1
- …
- 224
- 225
- 226
- 227
- 228
- …
- 531
- Next Page »